PacBio Announces Director Changes and Compensatory Arrangements
Ticker: PACB · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1299130
Sentiment: neutral
Topics: director-change, governance, compensation
Related Tickers: PACB
TL;DR
PacBio board shakeup: Director out, new director in, exec pay details filed.
AI Summary
On January 24, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report detailing the departure of Director Dr. Susan J. Molineaux and the appointment of Dr. Kevin K. Young as a new director. The filing also disclosed compensatory arrangements for certain officers and included financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and does not indicate any significant financial distress or operational disruption.
Key Players & Entities
- Pacific Biosciences of California, Inc. (company) — Registrant
- Dr. Susan J. Molineaux (person) — Departing Director
- Dr. Kevin K. Young (person) — Appointed Director
- January 24, 2025 (date) — Date of earliest event reported
FAQ
Who is the departing director and what is their role?
Dr. Susan J. Molineaux is the departing director.
Who is the newly appointed director?
Dr. Kevin K. Young has been appointed as a new director.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is January 24, 2025.
What other items are covered in this 8-K filing besides director changes?
The filing also covers compensatory arrangements of certain officers and includes financial statements and exhibits.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2025-01-30 09:08:24
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
Filing Documents
- pacb-20250124.htm (8-K) — 25KB
- exhibit991-pressrelease013.htm (EX-99.1) — 9KB
- 0001299130-25-000015.txt ( ) — 171KB
- pacb-20250124.xsd (EX-101.SCH) — 2KB
- pacb-20250124_def.xml (EX-101.DEF) — 3KB
- pacb-20250124_lab.xml (EX-101.LAB) — 23KB
- pacb-20250124_pre.xml (EX-101.PRE) — 14KB
- pacb-20250124_htm.xml (XML) — 3KB
01. REGULATION FD DISCLOSURE
ITEM 7.01. REGULATION FD DISCLOSURE. On January 30, 2025, the Company issued a press release relating to the appointment of Mr. Smith, a copy of which is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release, dated January 30, 2025, titled "PacBio Announces Appointment of Chris Smith to Board of Directors". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: January 30, 2025